| Cannabinoid CB1 and CB2 receptor-mediated arrestin translocation: species, subtype, and agonist-dependence MS Ibsen, DB Finlay, M Patel, JA Javitch, M Glass, NL Grimsey Frontiers in pharmacology 10, 350, 2019 | 72 | 2019 |
| Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA DB Finlay, JJ Manning, MS Ibsen, CE Macdonald, M Patel, JA Javitch, ... ACS chemical neuroscience 10 (10), 4350-4360, 2019 | 48 | 2019 |
| Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists M Patel, JJ Manning, DB Finlay, JA Javitch, SD Banister, NL Grimsey, ... Biochemical Pharmacology 175, 113871, 2020 | 46 | 2020 |
| Biased agonism at the cannabinoid receptors–evidence from synthetic cannabinoid receptor agonists M Patel, DB Finlay, M Glass Cellular Signalling 78, 109865, 2021 | 31 | 2021 |
| Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β‐arrestins and GPCR kinases M Patel, C Matti, NL Grimsey, DF Legler, JA Javitch, DB Finlay, M Glass British journal of pharmacology 179 (10), 2223-2239, 2022 | 9 | 2022 |
| Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor M Patel, NL Grimsey, SD Banister, DB Finlay, M Glass Pharmacology Research & Perspectives 11 (6), e01157, 2023 | 2 | 2023 |
| Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB1 receptor B Ryalls, M Patel, E Sparkes, SD Banister, DB Finlay, M Glass Biochemical Pharmacology, 116052, 2024 | 1 | 2024 |
| Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists M Patel, X Zheng, LR Akinfiresoye, C Prioleau, TD Walker, M Glass, ... European Journal of Pharmacology 971, 176549, 2024 | | 2024 |
| Molecular pharmacology of synthetic cannabinoid receptor agonists. Exploring potential mechanisms underpinning synthetic cannabinoid receptor agonist toxicity beyond activity … M Patel University of Otago, 2023 | | 2023 |
| ABM300, a new negative allosteric modulator of the CB1 cannabinoid receptor, exhibits a similar mechanism of action as ORG27569 N Khalajiassadi, D Finlay, M Patel, M Glass New Zealand Medical Association, 2021 | | 2021 |
